JanOne Inc. Agrees to Acquire Soin Therapeutics LLC

Servier Acquires Day One Biopharmaceuticals to Expand Rare Oncology Portfolio

March 6, 2026

Pharmaceuticals

Servier and Day One Biopharmaceuticals entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, valuing the deal at approximately $2.5 billion. The acquisition is expected to close in the second quarter of 2026 and is intended to strengthen Servier’s rare oncology and pediatric low-grade glioma positioning while expanding its clinical-stage pipeline.

Eli Lilly Acquires SiteOne Therapeutics

May 27, 2025

Biotechnology

Eli Lilly and Company announced a definitive agreement to acquire SiteOne Therapeutics, a clinical-stage biopharmaceutical company developing small-molecule inhibitors targeting sodium channels to treat pain. The deal is expected to expand Lilly’s non-opioid pain pipeline, including STC-004, a Phase 2-ready Nav1.8 inhibitor.

Otsuka Pharmaceutical Acquires Jnana Therapeutics

August 1, 2024

Biotechnology

Otsuka Pharmaceutical Co., Ltd. will acquire clinical-stage biotech Jnana Therapeutics, making it a wholly owned subsidiary via Otsuka America, Inc. The deal values Jnana at $800 million in upfront cash plus up to $325 million in development and regulatory milestones and is intended to add Jnana's RAPID chemoproteomics platform and lead program JNT-517 (a potential oral PKU therapy) to Otsuka's specialty and autoimmune pipeline.

Adalvo Acquires Branded Pain Product Onsolis

August 2, 2022

Pharmaceuticals

Adalvo has acquired full global rights to the branded opioid analgesic Onsolis from a U.S.-based specialty pharmaceutical owner, becoming the sole and exclusive owner of the product and assuming supply and market authorisation responsibilities worldwide. The product, indicated for management of breakthrough cancer pain in opioid-tolerant patients, is sold in several EU countries and Taiwan and Adalvo intends to integrate it into its expanding branded-product portfolio.

Trinity Hunt Partners Makes Initial Investment in SpineOne

January 13, 2022

Healthcare Services

Trinity Hunt Partners announced a partnership and initial investment in SpineOne, a Denver-area provider of interventional pain management services, and formed a new management services organization (MSO) to support the practice. Damon Green will serve as CEO of the MSO while SpineOne founder Dr. Perry Haney remains a significant shareholder; Trinity Hunt intends to build a national interventional pain management platform through affiliations with like-minded practices.

Shionogi Acquires Tetra Therapeutics

May 26, 2020

Biotechnology

Shionogi & Co., Ltd. agreed to acquire clinical-stage biopharmaceutical company Tetra Therapeutics, giving Shionogi global rights to Tetra's portfolio including BPN14770. The deal, announced May 26, 2020, is valued at up to $500 million in milestone and contingent payments.